ResearcherIstanbul Medeniyet UniversityActive in the last 2 years
Pınar Obakan Yerlikaya
Matched on ORCID iD 0000-0001-7058-955X; OpenAlex author ID A5003490576. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 3
- Chemopreventive Effects of Lycopene in miR-21 Knockout and Wild-Type Pancreatic Cancer Cells. Co-author DOI 10.1155/sci5/8865270↗
- Gemcitabine in combination with epibrassinolide enhanced the apoptotic response in an ER stress-dependent manner and reduced the epithelial-mesenchymal transit… Co-author DOI 10.55730/1300-0152.2630↗
- Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells. First author DOI 10.1002/jcb.29249↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elif Damla Arısan · 3 shared papers, 2020–2026 · strength 0.65
- Paper Chemopreventive Effects of Lycopene in miR-21 Knockout and Wild-Type Pancreatic Cancer Cells. DOI 10.1155/sci5/8865270↗
- Paper Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and … DOI 10.1002/jcb.29249↗
- Paper Gemcitabine in combination with epibrassinolide enhanced the apoptotic response in an ER stress-dependent manner and re… DOI 10.55730/1300-0152.2630↗
- Başak Dalbayrak · 1 shared paper, 2026 · strength 0.36
- Pinar Uysal Onganer · 1 shared paper, 2026 · strength 0.36
- Özge Rencüzoğulları · 2 shared papers, 2020–2022 · strength 0.29
- Paper Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and … DOI 10.1002/jcb.29249↗
- Paper Gemcitabine in combination with epibrassinolide enhanced the apoptotic response in an ER stress-dependent manner and re… DOI 10.55730/1300-0152.2630↗
- Dilek Telci · 1 shared paper, 2020 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.